Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Operating Leases (2022 - 2026)

Ovid Therapeutics filings provide 5 years of Operating Leases readings, the most recent being $11.6 million for Q1 2026.

  • Quarterly Operating Leases fell 11.16% to $11.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $11.6 million through Mar 2026, down 11.16% year-over-year, with the annual reading at $12.0 million for FY2025, 10.68% down from the prior year.
  • Operating Leases hit $11.6 million in Q1 2026 for Ovid Therapeutics, down from $12.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $16.2 million in Q3 2022 and bottomed at $11.6 million in Q1 2026.
  • Average Operating Leases over 5 years is $14.3 million, with a median of $14.4 million recorded in 2024.
  • The largest annual shift saw Operating Leases decreased 1.09% in 2023 before it decreased 11.16% in 2026.
  • Ovid Therapeutics' Operating Leases stood at $16.0 million in 2022, then fell by 7.78% to $14.8 million in 2023, then fell by 9.06% to $13.4 million in 2024, then decreased by 10.68% to $12.0 million in 2025, then dropped by 3.13% to $11.6 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Operating Leases are $11.6 million (Q1 2026), $12.0 million (Q4 2025), and $12.4 million (Q3 2025).